Skip to nav Skip to content
  • Cancer Type: Multiple Myeloma
  • Study Type: Other
  • NCT#:
  • Phase: N/A
Learn More
  • Overview

    Study Title:

    Real-World Clinical and Patient-Reported Outcomes Among Patients With Relapsed/Refractory Multiple Myeloma treated With Commercial CAR-T Therapy

    Summary:

    To date, little is known about the real-world clinical outcomes or PROs among Relapsed/Refractory Multiple Myeloma patients treated with SOC ide-cel and cilta-cel. This study will address this important gap in knowledge

    Objective:

    Aim 1: Describe real-world clinical outcomes (i.e., treatment response rates, incidence and severity of immune-mediated toxicities, progression-free and overall survival) among RRMM patients treated with SOC ide-cel and cilta-cel CAR-T therapy. Aim 2: Describe real-world PROs (i.e., HRQOL, symptom burden) among RRMM patients treated with SOC ide-cel and cilta-cel CAR-T therapy. Aim 3: Explore differences in clinical outcomes and PROs between RRMM patients treated with SOC ide-cel and cilta-cel CAR-T therapy

  • Inclusion Criteria

      Inclusion Criteria:
    • 18 years of age or older
    • Relapsed/Refractory Multiple Myeloma patients treated with standard of care ide-cel and cita-cel at Moffit
    • Able to speak and read English or Spanish
    • No documented or observable psychiatric or neurologic diagnoses that could interfere with participation (e.g., dementia, active psychosis)
    • Able to complete surveys on a smartphone, tablet, or computer with stable internet access
    • Able to provide informed consent
  • Exclusion Criteria

    If you are interested in learning more about clinical trials, our clinical trial navigators can discuss your options and recommend opportunities that may be suitable for you. Call 813-745-6100 or 1-800-679-0775 (toll-free) or submit a clinical trials inquiry form.

    Clinical Trial Search